- -- 29 September 2009
- immatics appoints Carsten Reinhardt as Chief Medical Officer
- -- 10 August 2009
- immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide
- -- 17 June 2009
- immatics biotechnologies significantly improves XPRESIDENT™ technology platform
- -- 02 March 2009
- immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer
- -- 26 January 2009
- immatics wins 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft)
- -- 23 January 2009
- Dr. Jürgen Frisch (Chief Medical Officer) to leave immatics
immatics appoints Carsten Reinhardt as Chief Medical Officer
Tuebingen, September 29, 2009 – immatics biotechnologies GmbH today announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009.
Dr Reinhardt’s background, qualifications and experience fit perfectly with the goals and expectations of immatics as the company looks to the rapid and further successful development of it’s lead clinical projects in renal cell carcinoma and colorectal cancer.
Dr Reinhardt joins immatics from Micromet, Inc., where he has headed the clinical development team for the past four years, initially as Senior Vice President, Clinical Development, and as Chief Medical Officer since June 2007. In this role, he was responsible for all corporate medical, clinical, and regulatory activities. During his tenure he headed the development team and moved various compounds into the clinic and successfully completed two key phase II studies. Dr. Reinhardt was also significantly involved in achieving Micromet’s public listing on NASDAQ through a reverse merger in 2006 and in repeated major financing rounds.
Before joining Micromet in 2005, Dr Reinhardt worked as International Medical Leader for Herceptin® at Hoffmann-La Roche (Basel, Switzerland) and before that as Head of Clinical Development at Fresenius Biotech (Munich, Germany), where he successfully developed later stage niche indication strategies leading to the recent approval of Removab®.
Prior to joining industry, Dr Reinhardt held medical positions and worked at various academic institutions (University of Tuebingen, Max Planck Institute, Munich) to complete his curriculum in Neurology. Between 1991 and 1995, Dr Reinhardt completed his Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany, and received a Medical Degree in 1994 from the University of Munich, Germany. He is a Visiting Professor for Pharmaceutical Medicine at the University of Basel.
“We are delighted to have been able to attract a CMO of Carsten‘s caliber and experience”, commented Paul Higham, CEO of immatics. “He has successfully moved immunotherapy products into late stage clinical development. This combined with Carsten’s experience of working within a successful biotech company and his in-depth knowledge of immunotherapy matched exactly the profile we were looking for, as we enter late stage clinical development.”
“I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt. “The encouraging results seen so far with the projects in clinical development and the high potential discovery platform both offer much promise in reaching the goals of immunotherapy in cancer treatment. I am looking forward to working with the team at immatics to realize this huge potential through successful late-stage clinical development of the lead projects.”